To the full analysis
Royalty Pharma stock: growth
RPRXRoyalty Pharma reported $2.38B in revenue for fiscal 2025, up 5.1% on the prior year, up 2.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
3.7%
per year from 2015 to 2025, per share 7.3%
Earnings (Annual rate)
2.9%
per year from 2015 to 2025, per share 9.3%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | |
|---|---|---|
| Revenue | 2.3% | 3.7% |
| Revenue per share | 0.1% | 7.3% |
| Earnings | −4.6% | 2.9% |
| Earnings per share | 12.7% | 9.3% |
| Free cash flow | 4.1% | no data |
| Free cash flow per share | 1.9% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2015 | $1.65B | $581.43M | $0 |
| 2016 | $1.88B | $565.91M | $0 |
| 2017 | $1.6B | $1.21B | $1.42B |
| 2018 | $1.79B | $1.38B | $1.62B |
| 2019 | $1.81B | $2.35B | $1.67B |
| 2020 | $2.12B | $975.04M | $2.03B |
| 2021 | $2.29B | $619.73M | $2.02B |
| 2022 | $2.24B | $42.83M | $2.14B |
| 2023 | $2.35B | $1.13B | $2.99B |
| 2024 | $2.26B | $858.98M | $2.77B |
| 2025 | $2.38B | $770.95M | $2.49B |
Revenue by segment
How Royalty Pharma plc makes its money and how that has shifted. Names are as the company reports them.
- Financial Royalty Assets95%
- Royalty Income, Other5%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| Financial Royalty Assets | $1.96B | $2.07B | $2.13B | $2.2B | $2.15B | $2.26B | 95.1% |
| Royalty Income, Other | $19M | $53.13M | $74.64M | $155.97M | $114.15M | $117.04M | 4.9% |
| Other | $143.38M | $171.25M | $37.48M | $0 | $0 | $0 | 0% |
| Total revenue | $2.12B | $2.29B | $2.24B | $2.35B | $2.26B | $2.38B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.